OKYO Pharma (OKYO) News Today $2.91 +0.30 (+11.49%) Closing price 03:59 PM EasternExtended Trading$2.90 -0.01 (-0.31%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period OKYO Pharma (NASDAQ:OKYO) Shares Down 13.7% - Should You Sell?June 18, 2025 | marketbeat.comOKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insidersJune 14, 2025 | uk.finance.yahoo.comOKYO Pharma poised for breakout as Phase 2 trial nears results: analystsJune 11, 2025 | proactiveinvestors.comGoldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock NewsJune 11, 2025 | gurufocus.comTokyo stocks edge down amid caution over U.S.-China trade tensionsJune 3, 2025 | msn.comOKYO Pharma (NASDAQ:OKYO) Stock Price Up 0.5% - Should You Buy?May 28, 2025 | marketbeat.comOKYO Pharma CEO to present drug research for debilitating eye pain at Boston summitMay 19, 2025 | proactiveinvestors.comOKYO Pharma CEO to Present at Boston Drug Discovery SummitMay 19, 2025 | tipranks.comOKYO Pharma to Present at the GPCRs-Targeted Drug Discovery SummitMay 19, 2025 | globenewswire.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painMay 1, 2025 | proactiveinvestors.comOKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painApril 30, 2025 | proactiveinvestors.comOKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal PainApril 30, 2025 | tipranks.comOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainApril 30, 2025 | globenewswire.comOKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIApril 5, 2025 | proactiveinvestors.comOKYO Pharma confirms stability of drug candidateApril 2, 2025 | uk.investing.comOKYO Pharma reports long-term shelf stability of corneal pain treatmentMarch 31, 2025 | proactiveinvestors.comOKYO Pharma Announces Positive Data in Long-Term Stability of UrcosimodMarch 31, 2025 | globenewswire.comOKYO Pharma Limited (NASDAQ:OKYO) Short Interest UpdateMarch 18, 2025 | marketbeat.comOKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal PainMarch 12, 2025 | nasdaq.comOKYO Pharma seeks FDA Fast Track for eye pain drugMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA fast track for eye pain treatmentMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatmentMarch 10, 2025 | proactiveinvestors.comOkyo Pharma files for FTD with FDA for urcosimodMarch 10, 2025 | markets.businessinsider.comOKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal PainMarch 10, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)February 18, 2025 | markets.businessinsider.comBuy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market PotentialFebruary 14, 2025 | tipranks.comOKYO Pharma secures USAN designation ‘urcosimod' for lead assetFebruary 12, 2025 | proactiveinvestors.comOKYO Pharma’s Lead Asset OK-101 Receives USAN as UrcosimodFebruary 12, 2025 | tipranks.comYi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory ChallengesFebruary 10, 2025 | tipranks.comOKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believeJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma insiders acquire sharesJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma Executives Increase Shareholdings, Affirming Market ConfidenceJanuary 31, 2025 | tipranks.comOKYO Pharma Announces Chairman and CEO Acquire SharesJanuary 31, 2025 | globenewswire.comOKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-endJanuary 29, 2025 | proactiveinvestors.comOKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second QuarterJanuary 29, 2025 | markets.businessinsider.comOkyo Pharma receives $1.4M in non-dilutive financingJanuary 23, 2025 | markets.businessinsider.comOKYO Pharma secures $1.4 million in non-dilutive fundingJanuary 22, 2025 | msn.comOKYO Pharma Receives $1.4 Million in Non-Dilutive FundingJanuary 22, 2025 | markets.businessinsider.comOKYO Pharma secures $1.4 million non-dilutive fundingJanuary 22, 2025 | msn.comOKYO Pharma secures non-dilutive funding to advance clinical programsJanuary 22, 2025 | proactiveinvestors.comOKYO Pharma Secures $1.4 Million to Boost Ophthalmic InnovationsJanuary 22, 2025 | tipranks.comMitsubishi Chemical picks Bain as preferred bidder for pharma unit, sources sayJanuary 21, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Veru (VERU)January 2, 2025 | markets.businessinsider.comOKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNovember 26, 2024 | markets.businessinsider.comOKYO Pharma to Highlight Innovations at BTIG ConferenceNovember 26, 2024 | tipranks.comJapan pharma mulls suing lawmaker who likened new COVID vaccine to 'biological weapon'November 2, 2024 | msn.comJapan's Takeda raises full-year profit forecast amid restructuringOctober 31, 2024 | msn.comOKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conferenceOctober 30, 2024 | proactiveinvestors.com Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address OKYO Media Mentions By Week OKYO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKYO News Sentiment▼1.890.90▲Average Medical News Sentiment OKYO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKYO Articles This Week▼01▲OKYO Articles Average Week Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GOSS News PRME News OLMA News AARD News SGMT News RCKT News LFCR News AVIR News IVA News TKNO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKYO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
